vs
Side-by-side financial comparison of HANMI FINANCIAL CORP (HAFC) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $71.2M, roughly 1.5× HANMI FINANCIAL CORP). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs -29.4%, a 59.3% gap on every dollar of revenue. On growth, HANMI FINANCIAL CORP posted the faster year-over-year revenue change (17.1% vs 16.9%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $-34.8M).
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
HAFC vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $71.2M | $103.7M |
| Net Profit | $21.2M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 29.8% | -31.7% |
| Net Margin | 29.8% | -29.4% |
| Revenue YoY | 17.1% | 16.9% |
| Net Profit YoY | 20.0% | 3.4% |
| EPS (diluted) | $0.70 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.2M | $103.7M | ||
| Q3 25 | $71.0M | — | ||
| Q2 25 | $65.2M | — | ||
| Q1 25 | $62.8M | — | ||
| Q4 24 | $60.8M | — | ||
| Q3 24 | $58.5M | — | ||
| Q2 24 | $56.7M | — | ||
| Q1 24 | $58.4M | — |
| Q4 25 | $21.2M | $-30.5M | ||
| Q3 25 | $22.1M | — | ||
| Q2 25 | $15.1M | — | ||
| Q1 25 | $17.7M | — | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $14.9M | — | ||
| Q2 24 | $14.5M | — | ||
| Q1 24 | $15.2M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 29.8% | -31.7% | ||
| Q3 25 | 31.1% | — | ||
| Q2 25 | 23.2% | — | ||
| Q1 25 | 28.1% | — | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 25.5% | — | ||
| Q2 24 | 25.5% | — | ||
| Q1 24 | 26.0% | — |
| Q4 25 | 29.8% | -29.4% | ||
| Q3 25 | 31.1% | — | ||
| Q2 25 | 23.2% | — | ||
| Q1 25 | 28.1% | — | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 25.5% | — | ||
| Q2 24 | 25.5% | — | ||
| Q1 24 | 26.0% | — |
| Q4 25 | $0.70 | $-0.50 | ||
| Q3 25 | $0.73 | — | ||
| Q2 25 | $0.50 | — | ||
| Q1 25 | $0.58 | — | ||
| Q4 24 | $0.58 | — | ||
| Q3 24 | $0.49 | — | ||
| Q2 24 | $0.48 | — | ||
| Q1 24 | $0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $796.4M | $456.1M |
| Total Assets | $7.9B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $796.4M | $456.1M | ||
| Q3 25 | $779.5M | — | ||
| Q2 25 | $762.8M | — | ||
| Q1 25 | $751.5M | — | ||
| Q4 24 | $732.2M | — | ||
| Q3 24 | $736.7M | — | ||
| Q2 24 | $707.1M | — | ||
| Q1 24 | $703.1M | — |
| Q4 25 | $7.9B | $638.1M | ||
| Q3 25 | $7.9B | — | ||
| Q2 25 | $7.9B | — | ||
| Q1 25 | $7.7B | — | ||
| Q4 24 | $7.7B | — | ||
| Q3 24 | $7.7B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $7.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.0M | $-24.8M |
| Free Cash FlowOCF − Capex | $203.7M | $-34.8M |
| FCF MarginFCF / Revenue | 286.2% | -33.5% |
| Capex IntensityCapex / Revenue | 3.2% | 9.6% |
| Cash ConversionOCF / Net Profit | 9.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.0M | $-24.8M | ||
| Q3 25 | $146.9M | — | ||
| Q2 25 | $-19.0M | — | ||
| Q1 25 | $25.8M | — | ||
| Q4 24 | $52.6M | — | ||
| Q3 24 | $6.7M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | $30.0M | — |
| Q4 25 | $203.7M | $-34.8M | ||
| Q3 25 | $146.4M | — | ||
| Q2 25 | $-19.6M | — | ||
| Q1 25 | $25.6M | — | ||
| Q4 24 | $49.9M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $29.2M | — |
| Q4 25 | 286.2% | -33.5% | ||
| Q3 25 | 206.3% | — | ||
| Q2 25 | -30.0% | — | ||
| Q1 25 | 40.7% | — | ||
| Q4 24 | 82.1% | — | ||
| Q3 24 | 11.1% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 50.0% | — |
| Q4 25 | 3.2% | 9.6% | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 9.70× | — | ||
| Q3 25 | 6.66× | — | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAFC
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
